Ipsen pays Day One $111M upfront for ex-US rights to pediatric brain tumor drug

Reynald Castañeda

Deputy Editor

In another move to boost its oncology portfolio, Ipsen is handing Day One Biopharmaceuticals $111 million upfront so it can take the pediatric brain tumor …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ipsen pays Day One $111M upfront for ex-US rights to pediatric brain tumor drug

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Ipsen pays Day One $111M up­front for ex-US rights to pe­di­atric brain tu­mor drug

Deputy Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Ipsen pays Day One $111M upfront for ex-US rights to pediatric brain tumor drug